TREATMENT AND PREVENTION

At present, there is no single specific antiviral therapy for CoV and the main treatments are supportive. Recombinant IFN with ribavirin only has limited effects against CoVs infection. After SARS and MERS epidemics, great efforts have been devoted to development of new antivirals targeting CoVs proteases, polymerases, MTases, and entry proteins, however, none of them has been shown to be efficacious in clinical trials. Plasma and antibodies obtained from the convalescent patients have been proposed for use in treatment.